Go to the profile of Glycostem

Glycostem

 
Go to the profile of HAOJUN LIAN
HAOJUN LIAN

BD, Innovent Biologics

TAHO is a specialty pharma focus on identifying, and developing new products that offer better therapeutic options to patient populations that may be under served. By utilizing company’s technology platform, it offers service niches in drug delivery. TAHO’s transdermal delivery platform allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. It transform the patient care by: . Continuous delivery, safe, reliable, and pain-free application . Improved convenience, tolerability, and dosing . Flexible drug administration TAHO’s transmucosal delivery system, delivery the drug as a thin film, an evolution from tablets or capsules. It is a better patient care with: . Convenient dosing, no water needed . No risk of choking . Taste masking Let TAHO be your partner for innovative solutions and diverse your product pipeline
ImmuneOncia was established as a joint venture between Sorrento Therapeutics, USA and Yuhan Corporation, Korea, focusing on immuno-oncology and aims to bring safe, effective immunotherapies to patients worldwide.
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

IsoPlexis is a life sciences company committed to advancing precision medicine in the fight against cancer, autoimmune and infectious diseases. The IsoPlexis single cell detection platform isolates single immune cells and analyzes their full functional response to assess the effectiveness of therapeutics and to predict patient clinical response. The newly introduced Isolight® Next Generation Single Cell Analysis system is a versatile precision engineering platform designed to understand and characterize differences among single cells, mapping thousands of cells per sample, to reveal full functional profiles and polyfunctionality among cell subsets to determine patient response and product quality.
YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologies by its founders. With this platform YUMAB generates antibody candidates with natural, close to germ-line sequences for lowest immunogenicity and with pre-designed properties (e.g., interspecies X-reactivity, large epitope coverage or targeted epitopes). The candidates are highly developable into several antibody drug formats like full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides customized solutions from target discovery and production, personalized antibody libraries, optimized antibody discovery strategies (also directly on cells) to close to germline antibody engineering and lead development with high success-rates even to difficult targets like GPCRs. YUMAB offers flexible business models from fee-for-service solutions to collaborative projects. Services are not limited to therapeutic development – it also contains recombinant antibody development for next-generation research and for diagnostic applications.
BIOCAD is Russia's leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the world's few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCAD`s medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.
Go to the profile of Serafim B. Tavares
Serafim B. Tavares

Independent Worker, Service Provider, [ (...) (e.g. Accountant / Auditor / Among others professional titles)], SBT, Serafim Bastos Tavares (SBT)

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature